We build trust in the safety of vaccines through rigorous science.
Case Definitions

This deliverable collates into a single document the SPEAC Spontaneous Abortion and Ectopic Pregnancy resources, including the ICD9/10-CM, MedDRA and SNOMED codes, background[...]

This document includes a Brighton Collaboration case definition of the term “Sensorineural Hearing Loss” (SNHL) as well as guidelines for data collection, analysis,[...]

This post contains the Companion Guide for Preterm Birth and Assessment of Gestational Age. This and other companion guides have been created as[...]

This is a Brighton Collaboration case definition of the term “Vaccine-associated Enhanced Disease” (VAED) to be utilized in the evaluation of adverse events[...]

This post contains the Companion Guide for Thrombosis and Thromboembolism. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]

This is a revision of the Brighton Collaboration Case Definition of the term “Anaphylaxis” to be utilized in the evaluation of adverse events[...]

This is a Brighton Collaboration Case Definition of the term “Myocarditis” and “Pericarditis” to be utilized in the evaluation of adverse events following[...]

Since February 2021, multiple countries have reported cases of Thrombosis with Thrombocytopenia Syndrome (TTS) in persons who received the COVID-19 vaccine. To further[...]

This post contains the Companion Guide for Generalized Convulsion. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]

This post contains the Companion Guide for Anaphylaxis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]

This post contains the Companion Guide for Facial Nerve Palsy. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]

This post contains the Companion Guide for Acute Disseminated Encephalomyelitis (ADEM). This and other companion guides have been created as part of the CEPI-funded SPEAC[...]

This post contains the Companion Guide for Acute Encephalitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]

This post contains the Companion Guide for Thrombocytopenia. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]

This post contains the Companion Guide for Aseptic Meningitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]

This post contains the Companion Guide for Guillain Barré and Miller Fisher Syndromes. This and other companion guides have been created as part[...]

This is a The Brighton Collaboration Case Definition of the term “Acute Respiratory Distress Syndrome (ARDS)” to be utilized in the evaluation of[...]

This is a Brighton Collaboration Case Definition of the terms “Multisystem Inflammatory Syndrome in Children (MIS-C)” and “Multisystem Inflammatory Syndrome in Adults (MIS-A)”[...]

This post contains the Companion Guide for Acute Myelitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]

Need for developing a case definition and guidelines for data collection, analysis, and presentation of wheeze as an adverse event following immunization Wheeze[...]
Vaccine Safety Templates

Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has[...]

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology[...]

Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development.[...]

The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological[...]

This paper uses a BRAVATO protein template to review the features of Medigen’s recombinant SARS-CoV-2 spike protein in prefusion stabilized form used to[...]

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform[...]

This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical[...]

This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery[...]

Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum[...]

Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]

Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared[...]

Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working[...]

This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vectored vaccines.[...]

In this paper, we use a standardized template describing key characteristics of the novel rVSV vaccine vectors, in comparison to wild type VSV. The template[...]

In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental[...]
News

This editorial by Dr. Robert T. Chen first appeared in the October 2023 issue of Safety by Numbers. It is reposted here with permission from[...]

Dear Brighton Collaboration members: Please find below a draft Brighton Collaboration case definition for both TTS (thrombosis and thrombocytopenia syndrome) and VITT (vaccine-induced[...]

This editorial was previously published in Vaccine Safety Quarterly. Karina Top, MD, MS Karina Top, MD, MS | Principal Investigator,[...]

On behalf of the Brighton Collaboration Autoimmune Hepatitis Case Definition Working Group, please find below a manuscript on “Autoimmune hepatitis: Brighton Collaboration case[...]

On behalf of the Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group, please find enclosed a manuscript and accompanying case[...]

On 8 and 9 November 2022, the Maternal Immunization Working Group (MIWG) held an in-person and online hybrid meeting. The objectives of the[...]

We are updating the Brighton website and need help from frequent users to advance requirements and provide design feedback. We will do this work[...]

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration, based in Atlanta at The Task Force for Global Health, announced the expansion of[...]

SPEAC has completed a fifth update to the Priority List of potential Adverse events of special interest relevant to COVID-19 vaccine trials. Past[...]

We are proud to announce that Dr. Bob Chen, Scientific Director of the Brighton Collaboration, received a special award for “Contributions to Public Health[...]

To help meet its increasing needs, the Secretariat for the Brighton Collaboration (BC) has recently posted a new staff position: Director of Research. The position[...]

Coalition for Epidemic Preparedness Innovations (CEPI) through the Safety Platform for Emergency vACcines (SPEAC) project, has funded the development of a training program for potential[...]

On behalf of the COVAX Vaccine Safety Working group: After COVID-19 vaccines are introduced into countries, it will be vital to generate real-world[...]

The current Brighton Collaboration Science Board has voted to accept all 16 candidates onto the new Brighton Collaboration Science Board. After consideration of[...]

SPEAC has completed a 4th update of the COVID-19 clinical literature covering the period from November 2020 – August 2021. Click HERE to[...]

We would like to announce the upcoming Brighton Collaboration Science Board election. The Science Board meets monthly for one hour to help determine[...]

As part of its role to support the assessment of safety of vaccines being evaluated in CEPI funded clinical trials, the Safety Platform[...]

Recent news of the possible complications of blood clots – or Thrombosis with Thrombocytopenia Syndrome (TTS) – following the AstraZeneca/Oxford and Johnson &[...]

The Benefit-Risk Assessment of Vaccines by TechnolOgy (BRAVATO) working group has developed standardized templates for the collection of key information for the development, efficacy, and[...]

The Centers for Disease Control and Prevention (CDC) has invested in The Task Force for Global Health (TFGH) to help low and middle income counties[...]

SPEAC has completed a second update of the COVID-19 clinical literature covering the period of August 8 through November 13th 2020. Based on this[...]